As of November 10, 2026, Evolus, Inc is a publicly traded company (Nasdaq: EOLS); its largest reported holder is Timothy P. Lynch, with 9.9% on Schedule 13G/A of February 17, 2026, then Nantahala Capital (8.85%). The largest insider holding is Simone Blank, a director, with 559,894 shares (0.85% of shares outstanding), per Form 4 of March 11, 2025 (Schedule 13G/A, February 17, 2026).
Is this your company?
About to sign with, pay or invest in Evolus, Inc? See the free Snapshot first.
Free to see. No signup.
Is Evolus, Inc a real, registered company?
- Evolus, Inc files with the SEC under CIK 1570562 (its SEC filings).
- Its shares are listed under the ticker EOLS on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Newport Beach, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Evolus, Inc in our court records and SEC 8-K records (as of 2026-11-10).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Soleus Capital Master Fund, L.P. (filed 2026-11-09).
Who are Evolus, Inc's owners and officers?
Evolus, Inc: incorporated in Delaware; business address in Newport Beach, California; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-11-09).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-11-09 | Soleus Capital Master Fund, L.P. | 7.7% |
| Schedule 13G, 2026-08-31 | Soleus Capital Master Fund, L.P. | 5.3% |
| Schedule 13G/A, 2026-03-26 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-02-17 | Timothy P. Lynch | 9.9% |
| Schedule 13G/A, 2026-02-17 | Caligan Partners LP | 0% |
| Schedule 13G/A, 2026-02-17 | Tang Capital Management, LLC | 1.92% |
| Schedule 13G/A, 2025-11-14 | Timothy P. Lynch | 7.9% |
| Schedule 13G/A, 2025-11-14 | Nantahala Capital Management, LLC | 8.85% |
| Schedule 13G/A, 2025-11-14 | Caligan Partners LP | 6.4% |
| Schedule 13G, 2025-08-18 | Timothy P. Lynch | 6.3% |
| Schedule 13G, 2025-08-14 | Caligan Partners LP | 5.2% |
| Schedule 13G/A, 2025-08-14 | Perceptive Advisors LLC | 3.8% |
Questions about who owns Evolus, Inc
Who owns Evolus, Inc?
On this page, 3 holders' latest ownership filings report 5% or more of Evolus, Inc: Timothy P. Lynch (9.9%, Schedule 13G/A, filed 2026-02-17), Nantahala Capital Management, LLC (8.85%, Schedule 13G/A, filed 2025-11-14) and Soleus Capital Master Fund, L.P. (7.7%, Schedule 13G/A, filed 2026-11-09).
Who are the largest shareholders of Evolus, Inc?
By the share each holder's latest filing reports, the largest holders of Evolus, Inc on this page are Timothy P. Lynch (9.9%), Nantahala Capital Management, LLC (8.85%) and Soleus Capital Master Fund, L.P. (7.7%).
When did Timothy P. Lynch buy into Evolus, Inc?
The filings give report dates, not purchase dates. The earliest filing from Timothy P. Lynch on this page is the Schedule 13G, filed 2025-08-18, reporting 6.3%; its latest, Schedule 13G/A filed 2026-02-17, reports 9.9%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Evolus, Inc?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Evolus, Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Evolus, Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Evolus, Inc shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 559,894 shares (0.85% of shares outstanding), 77,111 held directly and 482,783 indirectly (Form 4, 2025-03-11).
- , a director: 499,592 shares (0.75% of shares outstanding) (Form 4, 2026-09-04).
- Rui Avelar: 427,423 shares (0.65% of shares outstanding) (Form 4, 2026-03-20).
- , a director: 321,109 shares (0.49% of shares outstanding) (Form 4, 2026-02-19).
- , the chief financial officer: 226,092 shares (0.34% of shares outstanding) (Form 4, 2026-02-19).
Shares outstanding: 66,188,366 as of 2026-10-30, from the company's latest SEC cover page.
How much has Evolus, Inc raised?
No fundraising or offering filing from Evolus, Inc is on file with us.
Keep reading
More on Evolus, Inc and the records around it.
Evolus, Inc elsewhere on the record
- 5%+ stake filings Nov 2026
Companies that share a holder
- Timothy P. Lynch also filed stake reports on 1 other company: AEON Biopharma, Inc. (Aug 2026)
- Caligan Partners LP also filed stake reports on 9 other companies: Avalo Therapeutics, Inc. (Aug 2026), Cellectar Biosciences, Inc. (Aug 2026), Faeth Therapeutics, Inc. (Aug 2026)
- Soleus Capital Master Fund, L.P. also filed stake reports on 24 other companies: Beta Bionics, Inc. (Nov 2026), INSPIRE MEDICAL SYSTEMS, INC. (Nov 2026), NOVOCURE LIMITED (Nov 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/evolus